<unk>  is used to treat adults with complicated urinary tract infections, including kidney infections caused by susceptible Gram-negative microorganisms, who have limited or no alternative treatment options. In the United States,<unk>  is indicated in adults 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. For the treatment of severe pneumonia (HABP and VABP), it is indicated in patients 18 years of age and older whose pneumonia is not responding to other, more commonly used antibiotics and is confirmed to be caused by one of the following Gram-negative organisms: * Acinetobacter baumannii complex * Escherichia coli * Enterobacter cloacae complex * Klebsiella pneumoniae * Pseudomonas aeruginosa * Serratia marcescens This indication is supported by the APEKS-NP study, where<unk>  was compared to meropenem (a widely used antibiotic for multidrug-resistant bacteria causing pneumonia, among other diseases), where it was shown not to be inferior to meropenem. The primary endpoint of the study was all-cause mortality at day 14, where both antibiotics were shown to be almost equally effective. In the European Union,<unk>  is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
Cefiderocol
Sucralfate
Loperamide
Cefoperazone
Ornidazole
Cimetidine
Secnidazole
Lactulose